Company Capnia Inc Nasdaq
Equities
US14066L1052
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-13 | Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating | MT |
05-10 | Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Anish Bhatnagar
CEO | Chief Executive Officer | 56 | 31/12/05 |
James Mackaness
DFI | Director of Finance/CFO | 60 | 13/11/19 |
Ernest Mario
CHM | Chairman | 85 | 02/08/07 |
Kristen Yen
CTO | Chief Tech/Sci/R&D Officer | 55 | 31/12/05 |
Charles Horn
PRN | Corporate Officer/Principal | - | 31/12/21 |
Corporate Officer/Principal | - | 01-23 | |
Lauren Budesheim
HRO | Human Resources Officer | - | 01-23 |
Patricia Hirano
LAW | General Counsel | 58 | 31/03/17 |
Neil M. Cowen
PRN | Corporate Officer/Principal | - | 28/02/17 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ernest Mario
CHM | Chairman | 85 | 02/08/07 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 25/04/19 |
Bill Harris
BRD | Director/Board Member | 65 | 01/06/14 |
Anish Bhatnagar
CEO | Chief Executive Officer | 56 | 31/12/05 |
Andrew Sinclair
BRD | Director/Board Member | 52 | 20/12/18 |
Birgitte Volck
BRD | Director/Board Member | 61 | 09/06/19 |
Matthew Pauls
BRD | Director/Board Member | 53 | 14/08/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 34,678,159 | 31,162,511 ( 89.86 %) | 0 | 89.86 % |
Company contact information
Soleno Therapeutics, Inc.
203 Redwood Shores Parkway Suite 500
94065, Redwood City
+650 213 8444
http://www.soleno.lifeSector
1st Jan change | Capi. | |
---|---|---|
+9.58% | 115B | |
+12.41% | 107B | |
-2.59% | 21.6B | |
-12.38% | 22.31B | |
-5.29% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- SLNO Stock
- Stock
- Company Capnia Inc